Conflict of interest: Dr. Vaughan receives research support from Astellas. Dr. Trotti serves as a consultant and receives research support from UCB Pharma. Dr. Johnson serves as a consultant for Ferring, Vantia, Pfizer, and Johnson and Johnson and participated in trials for Pfizer and Vantia. Dr. Bliwise is a consultant for Vantia, New England Research Institute and Ferring.
Nocturia and overnight polysomnography in Parkinson disease
Article first published online: 28 JAN 2013
Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
Neurourology and Urodynamics
Volume 32, Issue 8, pages 1080–1085, November 2013
How to Cite
Vaughan, C. P., Juncos, J. L., Trotti, L. M., Johnson, T. M. and Bliwise, D. L. (2013), Nocturia and overnight polysomnography in Parkinson disease. Neurourol. Urodyn., 32: 1080–1085. doi: 10.1002/nau.22365
Christopher Chapple led the peer-review process as the Associate Editor responsible for the article.
- Issue published online: 24 OCT 2013
- Article first published online: 28 JAN 2013
- Manuscript Accepted: 3 DEC 2012
- Manuscript Received: 31 AUG 2012
- Supported by NINDS RO1 NS-050595 and PHS Grant UL1 RR025008 and KL2 RR025009 (Dr. Trotti) from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources. Dr. Vaughan is supported by a VA Rehabilitation R&D career development award (1IK2RX000747-01) and the John A. Hartford Foundation.
- Parkinson disease;
- sleep efficiency
Characterize clinical factors related to nocturia and sleep disruption in Parkinson disease (PD) using polysomnography (PSG).
Sixty-three PD patients were recruited regardless of sleep or voiding complaints from a university-based movement disorders clinic for a 48 hr inpatient PSG protocol. Nocturia frequency and bother related to urinary symptoms were assessed using the International Prostate Symptom Score (IPSS) and were corroborated by measurements of PSG-defined sleep made immediately preceding and subsequent to each in-lab voiding episode. PSG measures included whole-night total sleep time (TST), sleep efficiency (SE), apnea/hypopnea index (AHI), and time to PSG-defined sleep following nocturia episodes. Differences between groups were assessed using Mantel–Haenszel chi-square, t-tests, or Wilcoxon signed rank tests. Linear regression was used to assess factors associated with reported nocturia frequency.
Sixty patients completed the IPSS. Thirty-seven (61%) reported at least two nocturia episodes nightly; those individuals demonstrated lower PSG-defined SE (P = 0.01) and TST (P = 0.02) than patients with 0–1 episodes. Participants reporting 2–3 episodes of nocturia with high bother on the IPSS (n = 12) demonstrated lower whole-night TST (280.5 ± 116.1 min vs. 372.5 ± 58.7 min, P = 0.03) and worse SE (59.2 ± 22.7% vs. 75.9 ± 11.2%, P = 0.04) when compared to participants with 2–3 episodes of nocturia with low bother (n = 13).
These results verify objectively that PD patients with nocturia have poor sleep. Furthermore, among individuals with comparable levels of reported nocturia, higher bother is associated with poorer sleep as defined on PSG. Neurourol. Urodynam. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. Neurourol. Urodynam. 32:1080–1085, 2013.